A parliamentary inquiry into Rio Tinto’s destruction of ancient cultural sites could be stalled for months as the mining giant faces growing shareholder pressure.…
The Centre on Wednesday launched the Aatmanirbhar Bharat ARISE-Atal New India Challenges programme to support MSMEs and start-ups for making India innovative, resilient, tech-driven, and research and development (R&D)-oriented.
The Niti Aayog’s Atal Innovation Mission (AIM), in collaboration with ISRO and four ministries, will focus on challenges in 15 sectors through the programme.
“This support for MSMEs (micro, small and medium enterprises) and start-ups in product development would make India innovative, resilient, tech-driven and R&D-oriented,” Niti Aayog CEO Amitabh Kant said at the launch of the Aatmanirbhar Bharat ARISE-Atal New India Challenges programme.
He added that the programme provides a great opportunity for the government to become the first buyer of indigenous Made in India technology solutions.
Kant also expressed hope that the Atal Innovation Mission, through the ARISE-Atal New India Challenges, will help in breaking new ground and this will be a path-breaking approach for driving India in the field of innovation.
Also, speaking at the event, Niti Aayog Vice-Chairman Rajiv Kumar said this is a red-letter day for the country, as the Atal Innovation Mission’s ARISE-Atal New India Challenges brings together some of
In a major turn of events, the Indian drug regulator on Wednesday issued a show cause notice to Serum Institute of India (SII), which had earlier said it would proceed with clinical trials of AZD1222, the vaccine candidate developed by the University of Oxford, despite a halt on the same by AstraZeneca in the UK.
On Tuesday, the British-Swedish drug major had decided to stop trials after a participant fell sick with an unexplained illness.
Reacting to the show cause notice, a Serum spokesperson said:“We were going by the DCGI’s direction, and so far had not been told to pause trials. If the DCGI has any safety concerns, we will follow their instructions and abide by the standard protocols.”
Earlier during the day, the company had said that as far as Indian trials were concerned, they would continue as SII had faced “no issues at all”.
Investigators here, however, had expressed concerns during the day.
The lead investigator of one of the clinical trial sites in western India had said trials here should have, ideally, been paused as it was the same vaccine being administered to volunteers.
Once the highest-rated series in US cable television history, “The Walking Dead” is officially on its last legs.
The record-breaking zombie show will conclude in 2022 after a monster-sized 11th season spanning 24 episodes, network AMC said in a statement Wednesday.
“It’s been ten years ‘gone bye;’ what lies ahead are two more to come and stories and stories to tell beyond that,” said co-creator Scott Gimple.
Launched in 2010, the post-apocalyptic horror series repeatedly shattered cable audience records, peaking with the season five premiere in 2014, which drew 17.3 million viewers.
But audiences began declining steeply in 2017.
While the flagship show is now being killed off, the lucrative “Walking Dead” franchise has a lengthy afterlife planned.
AMC is forging ahead with a new spin-off focused on the characters Daryl Dixon (Norman Reedus) and Carol Peletier (Melissa McBride), to premiere in 2023.
A separate, anthology-style series will feature standalone episodes or groups of episodes focusing on individual characters — both existing favorites and new.
No release date was announced.
Another spin-off, “Fear the Walking Dead,” has been running since 2015, and “The Walking Dead: World Beyond” — a new series about the first generation raised in the apocalypse —